Company intelligence / Profile preview

Arcellx

Redwood City, California, United Statesarcellx.com ↗

Ownership: Public · ACLX
Development stage: Phase 3

Overview

Arcellx's lead candidate anitocabtagene autoleucel (anito-cel) has shown promising results in multiple myeloma with a 97% overall response rate and 62% complete response rate at a median follow-up of 9.5 months in the pivotal iMMagine-1 study. The Phase 1 study demonstrated durable benefit with a 30.2 month median progression-free survival. The safety profile has been manageable with no delayed neurotoxicities in 155 patients across Phase 1 and iMMagine-1 studies.

Therapeutic areas: OncologyNeurologyHematology
Modalities: Cell therapyCAR-T therapy
Industry: Biotech

Drug pipeline

9 assets

CART-BCMA

Approved

8 more assets in the full pipeline.

Request access →

Partnerships

Kite, a Gilead Company

Financials

Market cap: $6.7B
Total revenue: $1.7M
Enterprise value: $6.4B

Beyond the preview

Go deeper on Arcellx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arcellx.

Explore the full profile